Heron Therapeutics (HRTX) News Today $1.65 -0.03 (-1.79%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.comStockNews.com raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Wednesday.December 11, 2024 | marketbeat.comHeron Therapeutics Secures Revenue Stream with Court Ruling, Analyst Recommends BuyDecember 5, 2024 | markets.businessinsider.comHeron Therapeutics (NASDAQ:HRTX) Stock, Insider Trading ActivityDecember 5, 2024 | benzinga.comHeron Therapeutics patent victory removes ‘major overhang,’ says NorthlandDecember 5, 2024 | markets.businessinsider.comRelief For Heron Therapeutics After The Court Win On CinvantiDecember 4, 2024 | seekingalpha.comHeron Therapeutics’ patent of Cinvanti found valid by Delaware District CourtDecember 4, 2024 | markets.businessinsider.comU.S. District Court Upholds Validity of CINVANTI® PatentsDecember 3, 2024 | prnewswire.comHeron Therapeutics: Approved Therapy With Blockbuster Potential But Meager RevenuesNovember 30, 2024 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold"StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday.November 21, 2024 | marketbeat.comShort Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0%Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 28,810,000 shares, a decline of 6.0% from the October 15th total of 30,640,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is currently 15.7 days.November 18, 2024 | marketbeat.comQ4 EPS Forecast for Heron Therapeutics Reduced by AnalystHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Northland Capmk cut their Q4 2024 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the biotechnology company wNovember 15, 2024 | marketbeat.comHeron Therapeutics: Anticipating Q4 Recovery and Legal Resolution Justifies Buy RatingNovember 14, 2024 | markets.businessinsider.comHeron Therapeutics (HRTX) Gets a Buy from Northland SecuritiesNovember 14, 2024 | markets.businessinsider.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comHeron Therapeutics (NASDAQ:HRTX) Given New $4.00 Price Target at Needham & Company LLCNeedham & Company LLC decreased their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday.November 13, 2024 | marketbeat.comHeron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...November 13, 2024 | finance.yahoo.comHeron Therapeutics narrows 2024 revenue view to $140M-$146M from $138M-$158MNovember 13, 2024 | markets.businessinsider.comHeron Therapeutics, Inc.: Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial GuidanceNovember 12, 2024 | finanznachrichten.deHeron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comHeron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial GuidanceNovember 12, 2024 | prnewswire.comHeron Therapeutics Strengthens Leadership with New Board AppointmentNovember 5, 2024 | markets.businessinsider.comPositive Signs As Multiple Insiders Buy Heron Therapeutics StockNovember 5, 2024 | finance.yahoo.comHeron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641670)November 5, 2024 | marketbeat.comHeron Therapeutics Announces Appointment of Michael Kaseta to Board of DirectorsNovember 4, 2024 | prnewswire.comTop Performing High Short Interest StocksOctober 29, 2024 | benzinga.comHeron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024October 29, 2024 | prnewswire.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest UpdateHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 31,700,000 shares, a decline of 10.6% from the September 15th total of 35,440,000 shares. Based on an average daily volume of 2,200,000 shares, the short-interest ratio is currently 14.4 days.October 16, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLCMillennium Management LLC lowered its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 54.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,434,627 shares of the biotechnology compaOctober 12, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Congress Park Capital LLCCongress Park Capital LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 25.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,978,078 shares of the biotechnology company's stockOctober 11, 2024 | marketbeat.comHeron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous FluidsOctober 10, 2024 | prnewswire.comAQR Capital Management LLC Has $2.13 Million Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)AQR Capital Management LLC increased its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 1,460.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 607,135 shares of tOctober 9, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Squarepoint Ops LLCSquarepoint Ops LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 369.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 363,700 shares of the biotechnOctober 6, 2024 | marketbeat.comHeron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To ProfitabilityOctober 2, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Marshall Wace LLPMarshall Wace LLP lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 256.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,761,051 shares of the biotechnology company's stOctober 1, 2024 | marketbeat.comClearline Capital LP Sells 1,280,938 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Clearline Capital LP lessened its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 46.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,495,266 shares of the biotechnology compSeptember 29, 2024 | marketbeat.comRenaissance Technologies LLC Reduces Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)Renaissance Technologies LLC decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 17.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,993,800 shares of the biotechnology company's stockSeptember 26, 2024 | marketbeat.comHeron Therapeutics: A Buy Rating on FDA Approval and Positive Growth OutlookSeptember 25, 2024 | markets.businessinsider.comHeron Therapeutics' Zynrelef Vial Access Needle Receives FDA ApprovalSeptember 25, 2024 | markets.businessinsider.comHeron gains on FDA nod for new Zynrelef applicationSeptember 25, 2024 | msn.comHeron Therapeutics' (HRTX) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Heron Therapeutics in a report on Wednesday.September 25, 2024 | marketbeat.comHeron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")September 25, 2024 | prnewswire.comMonaco Asset Management SAM Cuts Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)Monaco Asset Management SAM trimmed its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 16.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,513,164 shares of the biotechnology company's stocSeptember 10, 2024 | marketbeat.comHeron Therapeutics Announces Appointment of Brett Fleshman as Chief Business OfficerSeptember 3, 2024 | prnewswire.comLegato Capital Management LLC Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX)Legato Capital Management LLC acquired a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 239,239 shares of the biotechnology company's stock, valued at approximately $837,0August 28, 2024 | marketbeat.comHeron Therapeutics, Inc. (0J4V.L)August 17, 2024 | nz.finance.yahoo.comHeron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Stock Quotes, Forecast and News SummaryAugust 8, 2024 | benzinga.comHeron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPSHeron Therapeutics (NASDAQ:HRTX - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). The company had revenue of $36.02 million during the quarter, compared to the consensus estimate of $35.35 million. During the same period in the previous year, the company posted ($0.35) EPS.August 7, 2024 | marketbeat.comHeron Therapeutics: Poised for Profitability Amid Growth CatalystsAugust 7, 2024 | markets.businessinsider.comHRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024August 6, 2024 | investorplace.com Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)Discover our #1 crypto for the Trump Presidency Bull Run now! (Available for a Short Time) We highly recommend this hot altcoin before prices get too high Check it out by going here now HRTX Media Mentions By Week HRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRTX News Sentiment▼0.940.75▲Average Medical News Sentiment HRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRTX Articles This Week▼02▲HRTX Articles Average Week Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Collegium Pharmaceutical News Today Septerna News Today Bicara Therapeutics News Today Zymeworks News Today Gyre Therapeutics News Today Poseida Therapeutics News Today Cogent Biosciences News Today Phibro Animal Health News Today Nuvation Bio News Today ArriVent BioPharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
